Loncom Pharma's Endocrine APIS, such as Ertugliflozin, Empagliflozin, Linagliptin, Prucalopride Succinate, and Vildagliptin, play a crucial role in antidiabetic and gastrointestinal medication development, providing targeted therapies for metabolic and endocrine disorders.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
